Sellas   Report issue

For profit Phase 2 Phase 3
Founded: New York NY United States (2006)

Organization Overview

First Clinical Trial
None
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
None

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 3 Trials (3)

Key: Sellas (0) Acquired (3)

galinpepimut-s (3 trials)

nelipepimut-s (3 trials)

sargramostim (leukine) (3 trials)

Drugs in Phase 2 Trials (3)

Key: Sellas (0) Acquired (3)

anagrelide (agrylin) (1 trial)

pembrolizumab (keytruda) (1 trial)

trastuzumab (herceptin) (2 trials)

Indications

Overview

  • Highest Phase: None
  • # of Trials: 7
  • # of Trial APIs: 6